UK markets closed

Biocon Limited (BIOCON.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
350.75-3.80 (-1.07%)
At close: 03:29PM IST
Full screen
Previous close354.55
Open355.00
Bid0.00 x 0
Ask0.00 x 0
Day's range349.10 - 356.00
52-week range217.50 - 373.85
Volume4,056,555
Avg. volume9,019,874
Market cap419.778B
Beta (5Y monthly)0.44
PE ratio (TTM)41.17
EPS (TTM)8.52
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yield0.50 (0.14%)
Ex-dividend date05 Jul 2024
1y target est301.12
  • Reuters

    India's Biocon posts Q4 profit fall as higher raw material costs bite

    Indian biopharmaceutical company Biocon reported a decline in its fourth-quarter profit on Thursday, as soaring raw material costs overshadowed growth in its biosimilar business in key United States and Europe markets. The company's consolidated net profit fell 56.6% to 1.36 billion rupees ($16.3 million) for the quarter ended March 31. Revenue from the company's generic drugs business fell 3.5%.

  • Reuters

    India's Biocon developing its own version of Wegovy, clinical trial likely next year

    Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.

  • Reuters

    UPDATE 1-Bristol Myers CEO says India to have largest R&D presence outside US by 2025

    U.S. drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday. The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference. Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International.